Suzetrigine vs Norco-postoperative Mohs Pain
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Norco 5Mg-325Mg Tablet, Suzetrigine.
- Who it may be relevant to
- Registry conditions: Cutaneous Tumors, Mohs Micrographic Surgery. Basic parameters: 18 years — 89 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Non-Opioid Pain Management After Mohs Reconstruction: An Investigator-Initiated, Prospective, Randomized Clinical Trial of Suzetrigine vs Hydrocodone/Acetaminophen
Overview
To compare suzetrigine versus hydrocodone/acetaminophen for postoperative pain control following dermatologic surgery.
Detailed description
This study is a randomized, controlled trial that is evaluating the safety and efficacy of suzetrigine as a postoperative pain medication compared to the standard of care Hydrocodone/Acetaminophen in patients undergoing Mohs micrographic surgery (MMS) who are at high-risk for postoperative pain and opioid use. The goal is to reduce opioid prescription use and give patients a non-opioid pain medication option for particularly painful surgeries. Patients will be randomized into one of two groups, one group will receive the interventional medication and the other the standard of care medication.
Interventions
- Drug Norco 5Mg-325Mg Tablet
Standard of care drug - Drug Suzetrigine
Control Drug
Primary outcome measures
- Change in need for opioid medication for pain management after Mohs micrographic surgery [Time frame: 48hours post surgery]
Secondary outcome measures (3)
- Patient-reported adequacy of pain control [Time frame: 48hours post surgery]
- Rescue pain management use [Time frame: 48hours post surgery]
- Adverse Events [Time frame: 3 days after surgery]
Eligibility criteria
Inclusion criteria
- adults between the age of 18-89
- individuals who have a cutaneous tumor treated by MMS
Exclusion criteria
- individuals younger than 18 and older than 89
- individuals taking medications that interact with the CYP3A (Cytochrome P450 3A) pathway
- individuals with liver disease
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Baylor University Medical Center — Dallas
Publications
- Ad Hoc Task Force; Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, Vidimos AT, Zalla MJ, Brewer JD, Smith Begolka W; Ratings Panel; Berger TG, Bigby M, Bolognia JL, Brodland DG, Collins S, Cronin TA Jr, Dahl MV, Grant-Kels JM, Hanke CW, Hruza GJ, James WD, Lober CW, McBurney EI, Norton SA, Roenigk RK, Wheeland RG, Wisco OJ. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs microg PMID 22959232
- Phillips, Shay, et al.
Identifiers
NCT: NCT07575230 · 025-413